Clinical bottom line
Emerging systemic therapies for chronic pruritic scalp dermatoses beyond psoriasis show promise in reducing itch and improving quality of life, but current evidence remains limited and largely extrapolated from psoriasis-focused studies. Safety profiles appear acceptable in early-phase trials, yet robust, scalp-specific efficacy and long-term safety data are sparse. Clinicians should cautiously consider these novel agents as adjuncts or alternatives when conventional treatments fail, pending further validation.
What the evidence shows
Chronic pruritic scalp dermatoses, including lichen planopilaris, chronic scalp eczema, and other inflammatory conditions, pose significant therapeutic challenges. While systemic therapies are well studied in scalp psoriasis, evidence for their use in other pruritic scalp disorders is emerging but not yet definitive.
Systemic biologics and small molecules approved for psoriasis have demonstrated scalp-specific efficacy, as reviewed by Greene et al. (2026), who highlighted that agents such as IL-17 and IL-23 inhibitors improve scalp lesions and pruritus in psoriasis patients. However, these data primarily derive from psoriasis cohorts, limiting direct applicability to other pruritic scalp diseases.
Beyond psoriasis, novel agents targeting pruritus pathways are under investigation. For example, KPL-716, a monoclonal antibody targeting oncostatin M receptor beta implicated in itch signaling, showed preliminary safety and efficacy in reducing pruritus in chronic pruritic diseases in a phase 2 study (Case Medical Research, 2019). While this trial included various pruritic conditions, scalp-specific outcomes were not separately reported, warranting cautious interpretation.
Traditional systemic therapies such as PUVA and UVB phototherapy have demonstrated efficacy in chronic plaque psoriasis, including scalp involvement, with acceptable safety profiles (Ahmed et al., 2022). However, their role in non-psoriatic pruritic scalp dermatoses remains unclear.
Safety data from systemic psoriasis treatments provide a useful reference. Kaushik et al. (2018) and Maul et al. (2017) reported that biologics and systemic agents generally have manageable safety profiles, but vigilance for infections and other adverse events is essential. Combining biologics with other systemic agents has been reviewed by Fife et al. (2003), emphasizing the need for careful monitoring.
Topical formulations such as UHE-105 shampoo and ARQ-154 foam have been studied for scalp psoriasis with favorable safety and efficacy signals (Case Medical Research, 2019; 2020), suggesting potential for adjunctive use in pruritic scalp conditions, though systemic data remain limited.
Caveats and uncertainty
The principal limitation is the paucity of high-quality, scalp-specific data for systemic therapies in chronic pruritic scalp dermatoses beyond psoriasis. Most evidence is extrapolated from psoriasis studies, which may not fully capture the pathophysiology or treatment response of other scalp conditions.
Heterogeneity in study populations, endpoints, and outcome measures complicates interpretation. Many trials do not report scalp-specific pruritus outcomes separately, limiting clinical applicability.
Long-term safety data for emerging systemic agents in these populations are lacking. The risk-benefit balance, especially in elderly or comorbid patients, remains uncertain.
Furthermore, the role of combination therapies and sequencing strategies has not been systematically evaluated in non-psoriatic scalp pruritus.
How this may change practice
Clinicians managing chronic pruritic scalp dermatoses beyond psoriasis should remain aware of emerging systemic options that target itch pathways and inflammatory mediators. While conventional systemic therapies and phototherapy remain mainstays, novel agents like KPL-716 may offer alternative mechanisms to address refractory pruritus.
Incorporating scalp-specific outcome assessments into clinical practice and trials will be critical to guide therapy selection. Until more definitive data emerge, systemic therapies approved for psoriasis may be cautiously considered off-label for select patients with severe, refractory pruritic scalp disease, with close monitoring.
Multidisciplinary collaboration and patient-centered discussions about the limited evidence base and potential risks are essential. Future research should prioritize randomized controlled trials focused on non-psoriatic scalp pruritus to inform evidence-based guidelines.